Clinical course and management of adrenal endocrine hypertension: A single-center experience
References
- Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, Mulatero P, Murad MH, Touyz RM, Vaidya A, Williams TA, Yang J, Young WF, Zennaro MC, Brito JP. Primary aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 110, 2453–2495, 2025.
- Akasaka H, Yamamoto K, Rakugi H, Nagasawa M, Nakamaru R, Ichijo T, Takeda Y, Kurihara I, Katabami T, Tsuiki M, Wada N, Ogawa Y, Kawashima J, Sone M, Kamemura K, Yoshimoto T, Matsuda Y, Fujita M, Kobayashi H, Watanabe M, Tamura K, Okamura S, Miyauchi S, Izawa S, Chiba Y, Tanabe A, Naruse M; Japan Primary Aldosteronism Study Group*. Sex difference in the association between subtype distribution and age at diagnosis in patients with primary aldosteronism. Hypertension 74, 368–374, 2019.
- Ananda RA, Gwini SM, Long KM, Lai JH, Chen G, Russell GM, Stowasser M, Fuller PJ, Yang J. Diagnostic delay and disease burden in primary aldosteronism: an international patient survey. Hypertension 81, 348–360, 2024.
- Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with Cushing’s syndrome. Front Endocrinol (Lausanne) 10, 321, 2019.
- Bioletto F, Bollati M, Lopez C, Arata S, Procopio M, Ponzetto F, Ghigo E, Maccario M, Parasiliti-Caprino M. Primary aldosteronism and resistant hypertension: a pathophysiological insight. Int J Mol Sci 23, 4803, 2022.
- Borozan S, Kamrul-Hasan ABM, Shetty S, Pappachan JM. Approach to endocrine hypertension: a case-based discussion. Curr Hypertens Rep 27, 8, 2025.
- Chung SM. Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review. J Yeungnam Med Sci 41, 269–278, 2024.
- Clemente-Gutierrez U, Perez-Soto RH, Hernandez-Acevedo JD, Iniguez-Ariza NM, Casanueva-Perez E, Pantoja-Millan JP, Sierra-Salazar M, Herrera MF, Velazquez-Fernandez D. Endocrine hypertension secondary to adrenal tumors: clinical course and predictive factors of clinical remission. Langenbecks Arch Surg 406, 2027–2035, 2021.
- De Freminville JB, Amar L, Azizi M, Mallart-Riancho J. Endocrine causes of hypertension: literature review and practical approach. Hypertens Res 46, 2679–2692, 2023.
- De Martino MC, Canu L, Bonaventura I, Vitiello C, Sparano C, Cozzolino A. Hypertension and Cushing’s syndrome: hunt for the red flag. J Endocrinol Invest 48, 1909–1918, 2025.
- Ebbehoj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, Robaczyk MG, Rasmussen AK, Feldt-Rasmussen U, Thomsen RW, Sondergaard E, Poulsen PL. Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study. J Clin Endocrinol Metab 106, e2251–e2261, 2021.
- Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, Alvarez-Escola C, Aristegui M, Bella-Cueto MR, Ferrer-Albiach C, Hanzu FA. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol 23, 1995–2019, 2021.
- Grigoryan S, Nhan W, Zhang L, Urban C, Zhao L, Turcu AF. Rates of pheochromocytoma/paraganglioma screening in at-risk populations. J Clin Endocrinol Metab 108, e343–e349, 2023.
- Heizhati M, Aierken X, Gan L, Lin M, Luo Q, Wang M, Hu J, Maimaiti N, Duiyimuhan G, Yang W, Yao L, Zhu Q, Li N. Prevalence of primary aldosteronism in patients with concomitant hypertension and obstructive sleep apnea, baseline data of a cohort. Hypertens Res 46, 1385–1394, 2023.
- Jha S, Sinaii N, McGlotten RN, Nieman LK. Remission of hypertension after surgical cure of Cushing’s syndrome. Clin Endocrinol (Oxf) 92, 124–130, 2020.
- Li Z, He Y, Zhang Y, Chen G, Zheng Y, Guo Y, Quan Z, Wu X. Predictive model for persistent hypertension after surgical intervention of primary aldosteronism. Sci Rep 13, 11868, 2023.
- Li SM, Huang JY, Zhu CY, Ng MY, Lin QS, Wu M, Liu MY, Wang R, Cao GZ, Chen C, Wu MZ, Ren QW, Tse HF, Yiu KH. Target organ damage in untreated hypertensive patients with primary aldosteronism. J Clin Hypertens (Greenwich) 26, 789–796, 2024.
- McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 45, 3912–4018, 2024.
- Park SS, Ahn CH, Kim SW, Koh JM, Lee SH, Kim JH. Temporal trends in clinical features of patients with primary aldosteronism over 20 years. Hypertens Res 47, 2019–2028, 2024.
- Parra Ramirez P, Rojas-Marcos PM, Paja Fano M, Gonzalez Boillos M, Pascual-Corrales E, Garcia-Cano A, Ruiz-Sanchez JG, Vicente A, Gomez-Hoyos E, Ferreira R, Garcia Sanz I, Recasens M, Pla Peris B, Barahona San Millan R, Picon Cesar MJ, Diaz Guardiola P, Jesus García Gonzalez J, Perdomo C, Manjon L, Garcia-Centeno R, Percovich JC, Rebollo Roman A, Gracia Gimeno P, Robles Lazaro C, Morales M, Hanzu F, Araujo-Castro M. Differences in the presentation and evolution of primary aldosteronism in elderly (≥65 years) and young patients (<65 years). Endocr Connect 11, e220169, 2022.
- Pillai K, Fares A, Dargham S, Al Suwaidi J, Jayyousi A, Abi Khalil C. Primary hyperaldosteronism is associated with increased mortality and morbidity in patients with hypertension and diabetes. Front Endocrinol (Lausanne) 14, 1147225, 2023.
- Romano S, Minuz P. Prevalence of hypertension: importance of epidemiologic studies and the need to spot undiag-nosed cases. Pol Arch Intern Med 134, 16784, 2024.
- Sanyal D, Mukhopadhyay P, Ghosh S. Prevalence and impact of diabetes and prediabetes on presentation and complications of primary hyperaldosteronism at diagnosis. World J Clin Cases 12, 3332–3339, 2024.
- Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ 385, e079108, 2024.
- Sugawara A, Shimada H, Otsubo Y, Kouketsu T, Yokoyama A. Primary aldosteronism and obstructive sleep apnea: the strong ties between them. Hypertens Res 46, 1712–1713, 2023.
- Turcu AF, Nhan W, Grigoryan S, Zhang L, Urban C, Liu H, Holevinski L, Zhao L. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J Am Heart Assoc 11, e025952, 2022.
- Zelinka T, Petrak O, Rosa J, Holaj R, Strauch B, Widimsky Jr. J. Primary aldosteronism and pregnancy. Kidney Blood Press Res 45, 275–285, 2020.
- Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am 40, 295–311, 2011.
Language: English
Page range: 221 - 230
Published on: Sep 19, 2026
Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 Ines Bayar, Hanene Sayadi, Farah Ayachi, Bilel Ben Amor, Sana Abid, Ekram Hajji, Hela Marmouch, Ines Khochtali, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.